FindMine: How Personalization Effects Brands

 
Over 89% of digital businesses are now investing in personalization marketing tactics. An individualized approach is said to hook the consumer, invite more interaction, and help boost sales. But investing in an individualized campaign is costly and it might not be all it’s made up to be. How should companies invest in their future without paying too much and losing their brand image in the process?

In this episode of “What Just Happened?” host Christine Russo invites guest Michelle Bacharach, CEO of FindMine to chat about brand personalization.

Contrary to many thought leaders of today, Bacharach believes personalization is a huge risk, one that can bankrupt a business. On one hand, personalization investment is increasing, but on the other, it is diminishing brand and editorial vision – which is arguably the one thing brands have that stands apart from giant retailers like Amazon.

“One of the reasons I started this business was that I believe that personalization can literally bankrupt businesses,” outlined Bacharach.

Russo and Bacharach discuss…

● The high-risk, low reward of buying into an individualized personalization market

● How brand differentiation rewards the consumer and the business

● Why FindMine implements a different approach to brand personalization while staying true to a scaled-out editorial vision for each company

“…what FindMine does is we’re a content-engine. We amplify the amount of editorial and inspirational content that’s available, sometimes by, you know, 10,000x what you have, and so if you can take that little nugget of…five assets that your marketing team feels great about and splice it and dice it and make it into a whole bunch of different flavors and varieties that are still on brand…but are different enough and dynamic enough to be appropriate for each of those people…you get a one-to-one story that’s possible…,” said Bacharach.

Bacharach has been the CEO of FindMine for over six years. She earned her BA in Interdisciplinary Studies from the University of California, Berkeley and her MBA from NYU’s Stern School of Business.

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More